Chronic lymphocytic leukemia

Current Opinion in Hematology

Volumn 5, Issue 4, 1998, Pages 244-253

  Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLIN DEPENDENT KINASE; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN G ANTIBODY; LYMPHOCYTE ANTIGEN; MELARSOPROL; PREDNISONE; PURINE DERIVATIVE; VINCRISTINE;

APOPTOSIS; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CHILL; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 6; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; FEVER; GENE THERAPY; GENETIC RISK; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN GENE; IMMUNOPATHOLOGY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; ONCOGENE; PRIORITY JOURNAL; RASH; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION; STRUCTURAL CHROMOSOME ABERRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRISOMY; TUMOR SUPPRESSOR GENE;

EID: 0032431803     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199807000-00003     Document Type: Review

References (124)

1. Neugut Al, Ahsan H, Robinson E, Ennis RD: Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 1997, 79:1600-1604.
2. Rushton L, Romaniuk H: A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom. Occup Environ Med 1997, 54:152-166.
3. McColl MD, Singer IO, Tait RC, McNeil IR, Cumming RL, Hogg RB: The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma - a regional association? Leuk Lymphoma 1997, 26:127-130.
4. Ferri C, La Civita L, Zignego AL, Pasero G: Hepatitis-C-virus infection and cancer [letter], Int J Cancer 1997, 71:1113-1115.
5. Feychting M, Forssen U, Floderus B: Occupational and residential magnetic field exposure and leukemia and central nervous system tumors. Epidemiology 1997, 8:384-389.
6. Adami HO, Tsaih S, Lambe M, Hsieh C, Adami J, Trichopoulos D, et al.: Pregnancy and risk of non-Hodgkin's lymphoma: a prospective study, Int J Cancer 1997, 70:155-158.
7. Garcia-Marco JA, Caldas C, Price CM, Wiedemann LM, Ashworth A, Catovsky D: Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia. Blood 1996, 88:1568-1575.
8. Panayiotidis P, Ganeshaguru K, Rowntree C, Jabbar SA, Hoffbrand VA, • Foroni L: Lack of clonal BCRA2 gene deletion on chromosome 13 in chronic lymphocytic leukaemia. Br J Haematol 1997, 97:844-847. Despite the report that the BRCA2 gene may be involved in greater than 80% of patients with CLL, this study failed to detect a single case of homozygous or heterozygous deletion of BCRA2 using probes for exons 11 and 26-27 of the BRCA2 gene (at 13q12) in the leukemia cells of 44 patients examined.
9. Garcia-Marco JA, Price CM, Catovsky D: Interphase cytogenetics in • chronic lymphocytic leukemia. Cancer Genet Cytogenet 1997, 94:52-58. Patients were investigated for 13q deletions using flourescent in situ hybridization analysis of the RB1 locus (13q14) and DNA probes for 13q12.3 (BRCA2) and 13q14 (RB1 and DBM locus). Twenty-eight of 35 (80%) cases showed deletion of a 1Mb 13q12.3 encompassing the BCRA2 locus, where as 22/35 (63%) were deleted at 13q14. These data suggest that abnormalities of 13q are more frequent than trisomy 12 in CLL and provide evidence for the presence of a new candidate gene at 13q12.3 that may be involved in the pathogenesis of CLL. However, deletions at 13q12.3 have yet to be observed by other investigators in CLL.
10. Crossen PE: Genes and chromosomes in chronic B-cell leukemia. Cancer • Genet Cytogenet 1997, 94:44-51. Trisomy 12 in association with complex karyotypic abnormalities is associated with a poor prognosis, and flourescent in situ hybridization studies show a strong correlation between trisomy 12, atypical morphology, and advanced disease. Ten percent to 15% of patients were found to have mutations of p53. The presence of such mutations was associated with advanced disease, resistance to treatment, and poor survival.
11. Gardiner AC, Corcoran MM, Oscier DG: Cytogenetic, fluorescence in situ hybridisation, and clinical evaluation of translocations with concomitant deletion at 13q14 in chronic lymphocytic leukaemia. Genes Chromosomes Cancer 1997, 20:73-81.
12. Dierlamm J, Michaux L, Criel A, Wlodarska I, Van den Berghe H, Hossfeld DK: Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet 1997, 94:27-35.
13. Einhorn S, Burvall K, Juliusson G, Gahrton G, Meeker T: Molecular analyses of chromosome 12 in chronic lymphocytic leukemia. Leukemia 1989, 3:871-874.
14. Crossen PE, Horn HL: Origin of trisomy 12 in B-cell chronic lymphocytic leukemia [letter]. Cancer Genet Cytogenet 1987, 28:185-186.
15. Matutes E: Trisomy 12 in chronic lymphocytic leukaemia [comment]. Leuk Res 1996, 20:375-377.
16. Sole F, Woessner S, Perez-Losada A, Florensa L, Montero S, Asensio A, • et al.: Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders. Cancer Genet Cytogenet 1997, 93:160-166. In a study of 76 patients with various chronic B-cell lymphoproliferative disease, abnormalities of chromosomes 6, 11, or 13 were observed most frequently in the leukemia cells of patients with common CLL, whereas trisomy 12 was frequently found in CLL mixed-cell type, in follicular lymphoma in leukemic phase, and chronic prolymphocytic leukemia.
17. Woessner S, Sole F, Perez-Losada A, Florensa L, Vila RM: Trisomy 12 is a rare cytogenetic finding in typical chronic lymphocytic leukemia [see comments]. Leuk Res 1996, 20:369-374.
18. Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R, et al.: Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996, 92:382-388.
19. Amiel A, Arbov L, Manor Y, Fejgin M, Elis A, Gaber E, Lishner M: • Monoallelic p53 deletion in chronic lymphocytic leukemia detected by interphase cytogenetics. Cancer Genet Cytogenet 1997, 97:97-100. This study found p53 gene mutations in leukemia cells of 10%-15% of patients with CLL. In addition, this study found a statistically significant correlation between p53 deletion and disease progression.
20. Brynes RK, McCourty A, Sun NC, Koo CH: Trisomy 12 in Richter's transformation of chronic lymphocytic leukemia. Am J Clin Pathol 1995, 104:199-203.
21. Shahidi H, Leslie WT, Wool NL, Gregory SA: Transformation of chronic lymphocytic leukemia to immunoblastic lymphoma (Richter's syndrome) [clinical conference], Med Pediatr Oncol 1997, 29:146-151.
22. Garcia-Marco J, Matutes E, Morilla R, Ellis J, Oscier D, Fantes J, et al.: Trisomy 12 in B-cell chronic lymphocytic leukaemia: assessment of lineage restriction by simultaneous analysis of immunophenotype and genotype in interphase cells by fluorescence in situ hybridization. Br J Haematol 1994, 87:44-50.
23. Mould S, Gardiner A, Corcoran M, Oscier DG: Trisomy 12 and structural abnormalities of 13q14 occurring in the same clone in chronic lymphocytic leukaemia. Br J Haematol 1996, 92:389-392.
24. Offit K, Louie DC, Parsa NZ, Filippa D, Gangi M, Siebert R, Chaganti RS: Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). Blood 1994, 83:2611-2618.
25. Demeter J, Porzsolt F. Ramisch S, Schmidt D, Schmid M, Messer G: • Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol 1997, 97:107-112. A provocative study that provides data indicating that patients with CLL possess an allele of the TNF-α gene that governs lower levels of inducible TNF-α more frequently than normal control subjects. The authors speculate that the risk for developing CLL is associated with a genetic polymorphism that influences the expression of this cytokine gene.
26. Cuneo A, Bigoni R, Negrini M, Bullrich F, Veronese ML, Roberti MG, et al.: • Cytogenetic and interphase cytogenetic characterization of atypical chronic lymphocytic leukemia carrying BCL1 translocation. Cancer Res 1997, 57:1144-1150. Flourescent in situ hybridization using yeast artifical chromosomes were used to probe for t(11;14), deletions on chromosome 11 at BCL-1, or deletions at 13q14 in CLL. Although some leukemia samples had deletions at BCL-1, these samples were atypical in morphology, shared immunologic features with mantle zone cell lymphoma, and were obtained from patients that had isolated peripheral blood and marrow lymphocytosis, with or without mild to moderate spleen involvement, and a more aggressive clinical course. Nevertheless, most the 13q14 deletions that typically are found in leukemia cells of patients with common CLL The authors suggest that these samples represent a variant of CLL that shares features of mantle zone cell lymphoma.
27. Hernandez JM, Mecucci C, Criel A, Meeus P, Michaux I, Van Hoof A, et al.: Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia 1995, 9:2140-2146.
28. Takashima T, Itoh M, Ueda Y, Nishida K, Tamaki T, Misawa S, et al.: Detection of 14q32.33 translocation and t(11;14) in interphase nuclei of chronic B-cell leukemia/lymphomas by in situ hybridization, Int J Cancer 1997, 72:31-38.
29. Dascalescu C, Gressin R, Callanan M, Sotto JJ, Leroux D: t(11;14)(q13;q32): chronic lymphocytic leukaemia or mantle cell leukaemia? [letter]. Br J Haematol 1996, 95:572-573.
30. Neilson JR, Fegan CD, Milligan DW: Mantle cell leukaemia? [letter]. Br J Haematol 1996, 93:494-495.
31. Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, et •• al.: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997, 89:2516-2522. These investigators examine the leukemia cells of 214 patients with B-CLL were studied by flourescent in situ hybridization using the yeast artifical chromosome clone 755b11 from chromosome region 11q22.3-q23.1. Forty-three (20%) had deletions in this region. Patients with 11q deletions were younger (P = 0.01). 11q deletions were associated with extensive peripheral, abdominal, and mediastinal lymphadenopathy (P < 0.001). Patients with 11q deletions had a more rapid disease progression as shown by a shorter treatment-free interval (9 months vs 43 months; P < 0.001). The prognostic effect of 11q deletion on survival strongly depended on the age: in patients less than 55 years old, the median survival time was significantly shorter in the deletion group (64 months vs 209 months; P < 0.001), whereas in patients greater than or equal to 55 years of age there was no significant difference (94 months vs 111 months; P = 0.82). The authors conclude that 11q deletions identifies a new clinical subset of CLL characterized by extensive lymph node involvement and, at least in younger patients, a shorter duration of survival.
32. Karhu R, Knuutila S, Kallioniemi OP, Siltonen S, Aine R, Vilpo L, Vilpo J: Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Tampere CLL Group. Genes Chromosomes Cancer 1997, 19:286-290.
33. Ueshima Y, Bird ML, Vardiman JW, Rowley JD: A 14;19 translocation in B-cell chronic lymphocytic leukemia: a new recurring chromosome aberration, Int J Cancer 1985, 36:287-290.
34. Michaux L, Mecucci C, Stul M, Wlodarska I, Hernandez JM, Meeus P, et al.: BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chromosomes Cancer 1996, 15:38-47.
35. McKeithan TW, Takimoto GS, Ohno H, Bjorling VS, Morgan R, Hecht BK, et al.: BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer 1997, 20:64-72.
36. Conchon M, McManus AP, Min T, Maljaie SH, Crawford A, Brito-Babapulle V, Matutes E, Catovsky D: Two unbalanced translocations, t(12;22)(p13;q11) and t(12;?)(p13;?), in an aggressive chronic B-cell leukemia: TEL gene analysis using FISH. Cancer Genet Cytogenet 1997, 95:137-140.
37. Yamada Y, Hatta Y, Murata K, Sugawara K, Ikeda S, Mine M, et al.: Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 1997, 15:1778-1785.
38. Martin JH, Edwards SW: Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactiveoxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing. J Immunol 1993, 150:3478-3486.
39. Williams ME, Whitefield M, Swerdlow SH: Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. Ann Oncol 1997, 8 Suppl 2:71-73.
40. Caligaris-Cappio F: B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996, 87:2615-2620.
41. Johnson TA, Rassenti LZ, Kipps TJ: Ig VH1 genes expressed in B-cell •• chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997, 158:235-246. This study demonstrates that the immunoglobulins expressed in CLL are not representative of those expressed by normal B cells. As such, this study provides the first compelling evidence that the immunoglobulins expressed in this disease are selected, suggesting that they play a role in the etiopathogenesis of this disease.
42. Matolcsy A, Casali P, Nador RG, Liu YF, Knowles DM: Molecular characterization of IgA- and/or IgG-switched chronic lymphocytic leukemia B cells. Blood 1997, 89:1732-1739.
43. Friedman DF, Moore JS, Erikson J, Manz J, Goldman J, Nowell PC, Silberstein LE: Variable region gene analysis of an isotype-switched (IgA) variant of chronic lymphocytic leukemia. Blood 1992, 80:2287-2297.
44. Ebeling SB, Schutte ME, Logtenberg T: Molecular analysis of VH and VL regions expressed in IgG-bearing chronic lymphocytic leukemia (CLL): further evidence that CLL is a heterogeneous group of tumors. Blood 1993, 82:1626-1631.
45. Hashimoto S, Dono M, Wakai M, Allen SL, Lichtman SM, Schulman P, et al.: Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med 1995, 181:1507-1517.
46. H genes with significantly more somatic mutations (6.5% ± 1.67%). These results suggest that the clonal history of the two subsets of CLL differ, thus challenging the notion that trisomy 12 is acquired during the course of disease progression.
47. Rassenti LZ, Kipps TJ: Lack of Allelic Exclusion in B cell chronic lympho•• cytic leukemia. J Exp Med 1997, 185:1435-1445. This study demonstrates that approximately 6% of patients with CLL have leukemic B cells that express more than one functional Ig heavy chain and therefore lack allelic exclusion.
48. Thompson AA, Talley JA, Do HN, Kagan HL, Kunkel L, Berenson J, et al.: •• Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 1997, 90:1387-1394. This study found that most CLL samples examined had somatic mutations predicted to affect expression and function of the immunoglobulin accessory protein, Ig-β (CD79b), that is required for the expression and signal transduction of surface immunoglobulin. The authors suggest that such aberations underlie the diminished expression and signaling capacity of surface immunoglobulin that appear characteristic of this leukemia.
49. Kobayashi R, Picchio G, Kirven M, Meisenholder G, Baird SM, Carson DA, Mosier DE, Kipps TJ: Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res 1992, 16:1013-1023.
50. Hummel JL, Lichty BD, Reis M, Dube I, Kamel-Reid S: Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Leukemia 1996, 10:1370-1376.
51. O'Brien S, Jeha S, Kantarjian H, Pisa P, Jin G, Keating M, Beran M: Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice. Leukemia 1996, 10:338-344.
52. Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K, et al.: Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996, 10:130-137.
53. Shimoni A, Marcus H, Canaan A, Ergas D, David M, Berrebi A, Reisner Y: A model for human B-chronic lymphocytic leukemia in human/mouse radiation chimera: evidence for tumor-mediated suppression of antibody production in low-stage disease. Blood 1997, 89:2210-2218.
54. Marcus H, Burakova T, Shezen E, David M, Canaan A, Lubin I, Reisner Y: Human → mouse radiation chimera do not develop Epstein-Barr virus lymphoma. Immunol Lett 1996, 49:155-161.
55. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB: Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1992, 89:2970-2974.
56. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82:1820-1828.
57. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996, 10:456-459.
58. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996, 156:2624-2630.
59. Gottardi D, Alfarano A, De Leo AM, Stacchini A, Aragno M, Rigo A, et al.: In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol 1996, 94:612-618.
60. Pepper C, Bentley P, Hoy T: Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996, 95:513-517.
61. Petersen AJ, Brown RD, Gibson J, Pope B, Luo XF, Schutz L, Wiley JS, Joshua DE: Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Eur J Haematol 1996, 56:213-220.
62. Tangye SG, Raison RL: Leukaemic CD5+ B-cell apoptosis: co-incidence of cell death and DNA fragmentation with reduced bcl-2 expression. Br J Haematol 1996, 92:950-953.
63. Agular-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M: Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression, Int J Cancer 1996, 69:114-119.
64. Smets LA, van den Berg JD: Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells. Leuk Lymphoma 1996, 20:199-205.
65. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80:879-886.
66. Coulie PG: Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today 1997, 3:261-268.
67. Boon T, Coulie PG, Van den Eynde B: Tumor antigens recognized by T cells, Immunol Today 1997, 18:267-268.
68. Thomas A, el Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996, 12:1055-1062.
69. Yang E, Korsmeyer SJ: Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996, 88:386-401.
70. McConkey DJ, Aguilar-Santelises M, Hartzell P, Eriksson I, Mellstedt H, Orrenius S, Jondal M: Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol 1991, 146:1072-1076.
71. Gottardi D, De Leo AM, Alfarano A, Stacchini A, Circosta P, Gregoretti • MG, et al.: Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations. Br J Haematol 1997, 99:147-157. This study found that fludarabine (9-beta-D-arabinofuranosyl-2-fluoradenine, Fara-A) down-regulated the expression of BCL-2 in 5 of 12 CLL samples tested in vitro. The down-regulation of BCL-2 mRNA was maximal at 48 hours, and bcl-2 protein down-regulation was prominent after 48 h. The authors provide data suggesting the susceptibility of leukemia cells to fludarabine-induced down modulation of bcl-2 correlated with the sensitivity to this drug in vivo.
72. Osorio LM, De Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M: CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 1997, 89:2833-2841.
73. Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J: CD6-ligand interactions: a paradigm for SRCR domain function? Immunol Today 1997, 18:498-504.
74. Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chhanabhai M, et al.: Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. Blood 1997, 89:3817-3825.
75. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 1997, 326:1-16.
76. Thornberry NA: The caspase family of cysteine proteases. Br Med Bull 1997, 53:478-490.
77. Bellosillo B, Dalmau M, Colomer D, Gil J: Involvement of CED-3/ICE • proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997, 89:3378-3384. This study indicates that CED-3 interleukin 1β-like converting enzyme-like proteases play an important role in the apoptosis of B-CLL cells induced by either dexamethasone or fludarabine.
78. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ: Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997, 97:409-417.
79. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin 4 protects chronic lymphocylic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992, 176:1319-1326.
80. Pu QQ, Bezwoda WR: Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitizes B-CLL cells to melphalan cytotoxicity. Br J Haematol 1997, 98:413-417.
81. Dutcher JP, Venkatraj U, Makower D, Wiernik PH: Interleukin-4 is a pleotropic cytokine with effects on B-cell malignancies [comment]. Leuk Res 1997,21:17-19.
82. Tangye SG. Raison RL: Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bd-2. Immunol Cell Biol 1997, 75:127-135.
83. Mu X, Kay NE, Gosland MP, Jennings CD: Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CDS T cells. Br J Haematol 1997, 96:733-735.
84. Frankfurt OS, Byrnes JJ, Villa L: Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients [see comments]. Leuk Res 1997, 21:9-16.
85. Jurlander J, Lai CF, Tan J, Chou CC, Geisler CH, Schriber J, Blumenson LE, Narula SK, Baumann H, Caligiuri MA: Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 1997, 89:4146-4152.
86. Lotz M, Ranheim E, Kipps TJ: Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994, 179:999-1004.
87. Lagneaux L, Delforge A, Bron D, Massy M, Bernier M, Stryckmans P: Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-beta receptors. Br J Haematol 1997, 97:612-620.
88. Van Oers MH, Pals ST, Evers LM, van der School CE, Koopman G, Bonfrer JM, Hintzen RQ, von dem Borne AE, van Lier RA: Expression and release of CD27 in human B-cell malignancies. Blood 1993, 82:3430-3436.
89. Ranheim EA, Cantweli MJ, Kipps TJ: Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995, 85:3556-3565.
90. Kato K, Cantwell MJ, Sharma S, Kipps TJ: Gene transfer of CD40-ligand •• induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998, 101:1133-1141. Using replication defective adenovirus encoding CD154 (Ad-CD154), CLL B cells were modified to express a functional ligand for CD40. This not only induced expression of immune accessory molecules on the infected leukemia cell, but also allowed it to transactivate noninfected bystander leukemia B cells into highly effective antigen-presenting cells that were capable of inducing generation of cytotoxic T lymphocytes specific for autologous non-modified leukemia cells. This strategy may allow for immuno-gene therapy of this disease.
91. Cantwell MJ, Hua T, Pappas J, Kipps TJ: Acquired CD40-ligand deficiency •• in patients with chronic lymphocytic leukemia. Nature Med 1997, 3:984-989. This study demonstrates that CLL B cells effectively down-modulate expression of the CD40-ligand (CD154) on activated T cells, thus precluding expression of this important immune accessory molecule. This activity likely contributes to the immune deficiency that is acquired by patients with this disease, an immune deficiency that shares many features with that of patients who have a genetic defect in the expression of CD40-ligand.
92. Grewal IS, Flavell RA: The CD40 ligand. At the center of the immune universe? Immunol Res 1997, 16:59-70.
93. Oscier DG, Matutes E, Copplestone A, Pickering RM, Chapman R, • Gillingham R, Catovsky D, Hamblin TJ: Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol 1997, 98:934-939. In a univariate analysis the presence of trisomy 12 was found to correlate with progressive disease, but this was largely a consequence of the association between trisomy 12 and atypical lymphocyte morphology. The authors conclude that atypical lymphocyte morphology is an important prognostic factor in stage A CLL.
94. Montserrat E, Bosch F, Rozman C: B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol 1997, 8 Suppl 1:93-101.
95. Tefferi A, Bartholmai BJ, Witzig TE, Jenkins RB. Li CY, Hanson CA, et al.: Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1997, 95:173-177.
96. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, et al.: Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996, 88:4259-4264.
97. Knauf WU, Ehlers B, Mohr B, Thiel E, Langenmayer I, Hallek M, et al.: Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia [letter]. Blood 1997, 89:4241-4242.
98. Spati B, Child JA, Kerruish SM, Cooper EH: Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. A multicentre study. Acta Haematol 1980, 64:79-86.
99. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, et al.: Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996, 22:439-447.
100. Everaus H, Luik E, Lehtmaa J: Active and indolent chronic lymphocytic leukaemia-immune and hormonal peculiarities. Cancer Immunol Immunother 1997, 45:109-114.
101. Beaudreuil J, Lortholary O, Martin A, Feuillard J, Guillevin L, Lortholary P, et al.: Hypercalcemia may indicate Richter's syndrome: report of four cases and review. Cancer 1997, 79:1211-1215.
102. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S: Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995, 85:2315-2320.
103. Ohyashiki K, Ohyashiki JH: Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. Cancer Genet Cytogenet 1997, 94:67-72.
104. Domingo A, Gonzalez-Barca E, Castellsague X, Fernandez-Sevilla A, Granena A, Crespo N, Ferran C: Expression of adhesion molecules in 113 patients with B-cell chronic lymphocytic leukemia: relationship with clinico-prognostic features. Leuk Res 1997, 21:67-73.
105. Kipps TJ: Chronic lymphocytic leukemia. Current Opinion in Hematology 1997, 4:268-276.
106. Jaksic B, Brugiatelli M, Krc I, Losonczi H, Holowiecki J, Planinc-Peraica A, • et al.: High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997, 79:2107-2114. This study found that high-dose chlorambucil was an effective and well-tolerated treatment for patients with advanced or progressive CLL. The authors recommend its wider use, possibly in comparison with or in combination with new therapeutic agents, such as purine analogues.
107. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al.: Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989, 74:19-25.
108. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD: Treatment of • refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 1997, 15:458-465. This study describes the toxicity and activity of fludarabine in refractory CLL in a setting that more closely resembles clinical practice than most published trials.
109. Gjedde SB, Hansen MM: Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. Leuk Lymphoma 1996, 21:317-320.
110. Angelopoulou MA, Poziopoulos C, Boussiotis VA, Kontopidou F, Pangalis GA: Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response. Leuk Lymphoma 1996, 21:321-324.
111. O'Brien S, Kantarjian H, Beran M, Koller C, Talpaz M, Lerner S, Keating • MJ: Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997, 11:1631-1635. The study found that administration of granulocyte colony-stimulating factor following fludarabine could reduce the incidences of myelosuppression and infections compared with historical controls.
112. Konig A, Wrazel L, Warrell RPJ, Rivi R, Pandolfi PP, Jakubowski A, Gabrilove JL: Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997, 90:562-570.
113. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, •• Mellstedt H: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567-1574. This study found that CAMPATH-1H had significant activity in patients with advanced and chemotherapy-resistant CLL.
114. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D: Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997, 96:617-619.
115. Dyer MJ, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, et al.: In • vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol 1997, 97:669-672. This study suggests that treatment with CAMPATH-1H may be of value in eradicating residual disease in CLL and facilitate high-dose therapy in young patients.
116. Shen S, DeNardo GL, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ: Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer 1997, 80:2553-2557.
117. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer 1997, 80:2706-2711.
118. Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ: Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 1997, 15:52-60.
119. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al.: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996, 124:311-315.
120. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, et al.: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88:2228-2235.
121. Gahn B, Schafer C, Neef J, Troff C, Feuring-Buske M, Hiddemann W, •• Wormann B: Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Blood 1997. 89:4275-4281. This study found that trisomy 12 and Rb-deletion may be present in the CD34+ stem cells of patients with CLL, suggesting that the malignant transformation in B-CLL may involve early hematopoietic stem cells that have yet to undergo B cell differentiation.
122. Gahn B, Schafer C, Neef J, Troff C, Feuring-Buske M, Hiddemann W, Wormann B: Detection of trisomy 12 in CD34+ progenitor cells in a patient with B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization. Ann Oncol 1997, 8 Suppl 2:55-57.
123. Gribben JG: Bone marrow transplantation for low-grade B-cell malignan• cies. Curr Opin Oncol 1997, 9:117-121. This article reviews current concepts and trends in cell transplantation for clinical diseases that are relevant to chronic lymphocytic leukemia.
124. Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, et • al.: Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997, 97:466-473. This study suggests that allogeneic-stem-cell transplantation can induce durable remission in patients with CLL refractory to fludarabine. It also suggests that prior exposure to fludarabine may decrease the incidence to severe acute graft versus host disease, possibly through its immunosuppressive effects.